3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Breast Neoplasms
114
Stomach Neoplasms
19
HER2-positive Breast Cancer
14
Neoplasms
12
Neoplasm Metastasis
12
Colorectal Neoplasms
11
Esophageal Neoplasms
9
Triple Negative Breast Neoplasms
5
Lung Neoplasms
5
Colonic Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Brain Neoplasms
5
Rectal Neoplasms
4
Ovarian Neoplasms
4
Meningeal Neoplasms
4
Endometrial Neoplasms
4
Biliary Tract Neoplasms
4
Adenocarcinoma Of Esophagus
4
Uterine Cervical Neoplasms
3
Salivary Gland Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Meningeal Carcinomatosis
3
Lymphoma, Non-Hodgkin
3
Inflammatory Breast Neoplasms
3
Hematologic Neoplasms
3
Gallbladder Neoplasms
3
Breast Diseases
3
Anatomic Stage I Breast Cancer AJCC v8
3
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
Trastuzumab
×
1 year
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled